Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation

[1]  M. Loda,et al.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. , 2019, European urology.

[2]  R. Bjerkvig,et al.  Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy , 2018, Autophagy.

[3]  Colm J. Ryan,et al.  Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer , 2018, Oncogene.

[4]  Ling Zhang,et al.  Overactivated neddylation pathway in human hepatocellular carcinoma , 2018, Cancer medicine.

[5]  D. Faller,et al.  Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. , 2018, Blood.

[6]  Mallikarjuna Korivi,et al.  Chalcone flavokawain B induces autophagic-cell death via reactive oxygen species-mediated signaling pathways in human gastric carcinoma and suppresses tumor growth in nude mice , 2017, Archives of Toxicology.

[7]  H. He,et al.  Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. , 2016, Cell reports.

[8]  M van Duin,et al.  Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma , 2016, Leukemia.

[9]  G. Mulligan,et al.  A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma , 2016, Investigational New Drugs.

[10]  G. Mulligan,et al.  Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma , 2015, Clinical Cancer Research.

[11]  Jeffrey W. Clark,et al.  Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[12]  F. Zhan,et al.  NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma , 2015, Clinical Cancer Research.

[13]  M. Maris,et al.  Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study , 2015, British journal of haematology.

[14]  A. Omar,et al.  In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice , 2015, Drug design, development and therapy.

[15]  M. Peter,et al.  Protein neddylation: beyond cullin–RING ligases , 2014, Nature Reviews Molecular Cell Biology.

[16]  P. Nordlund,et al.  The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.

[17]  Q. Gao,et al.  Overactivated neddylation pathway as a therapeutic target in lung cancer. , 2014, Journal of the National Cancer Institute.

[18]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[19]  X. Zi,et al.  Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis , 2013, Molecular Cancer.

[20]  M. Rubin,et al.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.

[21]  M. Lilly,et al.  Kava Components Down-Regulate Expression of AR and AR Splice Variants and Reduce Growth in Patient-Derived Prostate Cancer Xenografts in Mice , 2012, PloS one.

[22]  K. Knudsen,et al.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer , 2011, Nature Reviews Urology.

[23]  P. Nelson,et al.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. , 2010, The Journal of clinical investigation.

[24]  Zhongbo Liu,et al.  Flavokawain B, a kava chalcone, induces apoptosis via up‐regulation of death‐receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth , 2010, International journal of cancer.

[25]  P. Chueh,et al.  Flavokawain B, a novel chalcone from Alpinia pricei Hayata with potent apoptotic activity: Involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116 cells. , 2010, Free radical biology & medicine.

[26]  W. Dubiel.  Resolving the CSN and CAND1 paradoxes. , 2009, Molecular cell.

[27]  R. Osman,et al.  Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail , 2008, Proceedings of the National Academy of Sciences.

[28]  C. Hawkey,et al.  Characterization of cullin-based E3 ubiquitin ligases in intact mammalian cells--evidence for cullin dimerization. , 2007, Cellular signalling.

[29]  A. Stoffel,et al.  Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. , 2006, Cancer research.

[30]  X. Zi,et al.  Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. , 2005, Cancer research.

[31]  W. Krek,et al.  The F‐box protein Skp2 is a ubiquitylation target of a Cul1‐based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts , 2000, The EMBO journal.

[32]  Y. Xiong,et al.  Human CUL-1, but not other cullin family members, selectively interacts with SKP1 to form a complex with SKP2 and cyclin A. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  Joseph Locker,et al.  Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice , 2010, Nature Genetics.